What Investors Should Know About a Viking Therapeutics Insider's $2 Million Stock Sale

Greg Zante, the chief financial officer of Viking Therapeutics (NASDAQ:VKTX), reported the direct sale of 57,661 shares of the biotech in multiple open-market transactions valued at $1.9 million, according to a recent SEC Form 4 filing.Transaction value based on SEC Form 4 weighted average purchase price ($32.90); post-transaction value based on position value at the Monday transaction price.Viking Therapeutics is a clinical-stage biotechnology company focused on advancing novel therapies for metabolic and endocrine diseases. With a lean team and a diversified pipeline, the company aims to address significant unmet medical needs through innovative small molecule therapeutics. Its strategic emphasis on selective receptor modulators positions it to compete in high-value specialty pharmaceutical markets as its assets progress through clinical development.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool